Literature DB >> 11559315

Cognitive deficits associated with a recently reported familial neurodegenerative disease: familial encephalopathy with neuroserpin inclusion bodies.

C B Bradshaw1, R L Davis, A E Shrimpton, P D Holohan, C B Rea, D Fieglin, P Kent, G H Collins.   

Abstract

BACKGROUND: We recently discovered an autosomal dominant disease causing a progressive dementia. The disease is caused by a point mutation in the gene coding for the serine protease inhibitor (ie, serpin) neuroserpin. The mutation results in an unstable neuroserpin protein that readily aggregates into intraneuronal inclusions that we identify as Collins bodies. The bodies are distributed throughout the cerebral hemispheres but are significantly more numerous in the cortex and the substantia nigra. We have named the disease familial encephalopathy with neuroserpin inclusion bodies (FENIB).
OBJECTIVES: To describe the cognitive and neurophysiological changes exhibited by individuals with FENIB and to correlate the phenotypic expression of the disease with the neuropathological findings.
DESIGN: Multiple case studies using neuropsychological assessment, electroencephalography (EEG), magnetic resonance imaging (MRI), and single-photon emission computed tomographic (SPECT) studies of family members were performed. Using these measures, we also compared family members in whom the mutation is present with family members in whom the mutation was absent to control for nonspecific familial factors.
SUBJECTS: Nine individuals (5 women, aged 31-64 years; 4 men, aged 43-67 years) from 2 generations of family members related to the first reliably identified individual with symptoms of this disease. Symptoms, by self-report and reports of other family members, ranged from asymptomatic to severe dementia. Six of the 9 individuals carried the disease mutation.
RESULTS: All subjects with the mutation demonstrated some cognitive changes, with the greatest demonstrated by subjects older than 40 years. The changes included restricted attention, concentration, and response regulation functions, reduced controlled oral fluency (word-list generation), and restricted visuospatial organization. In general, recall memory was not as affected as other cognitive domains. The most severely affected subject demonstrated global dementia with prominent frontal lobe features. Findings on SPECT showed anomalies limited to frontal areas in the less affected subjects and more global, patchy areas of hypoperfusion in the more severely affected subjects. The 3 oldest and most affected subjects demonstrated slowing on EEG findings. The MRI findings were noncontributory except in the 2 most severe cases, which showed global cortical atrophy.
CONCLUSIONS: Cognitive changes in mildly to moderately affected subjects were characterized by deficits in frontal and frontal-subcortical area-dependent processes. Continued progressive deterioration of cerebral functions with relative sparing of recall memory suggests a unique dementia associated with this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559315     DOI: 10.1001/archneur.58.9.1429

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

2.  Accumulation of mutant neuroserpin precedes development of clinical symptoms in familial encephalopathy with neuroserpin inclusion bodies.

Authors:  Giovanna Galliciotti; Markus Glatzel; Jochen Kinter; Serguei V Kozlov; Paolo Cinelli; Thomas Rülicke; Peter Sonderegger
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 3.  Protein misfolding and the serpinopathies.

Authors:  Didier Belorgey; Peter Hägglöf; Susanna Karlsson-Li; David A Lomas
Journal:  Prion       Date:  2007-01-06       Impact factor: 3.931

Review 4.  The diagnosis of young-onset dementia.

Authors:  Martin N Rossor; Nick C Fox; Catherine J Mummery; Jonathan M Schott; Jason D Warren
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

5.  Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene.

Authors:  Matthew C Hagen; Jill R Murrell; Marie-Bernadette Delisle; Eva Andermann; Frederick Andermann; Marie Christine Guiot; Bernardino Ghetti
Journal:  Brain Pathol       Date:  2011-03-24       Impact factor: 6.508

Review 6.  Neuroserpin, a crucial regulator for axogenesis, synaptic modelling and cell-cell interactions in the pathophysiology of neurological disease.

Authors:  Angela Godinez; Rashi Rajput; Nitin Chitranshi; Veer Gupta; Devaraj Basavarajappa; Samridhi Sharma; Yuyi You; Kanishka Pushpitha; Kunal Dhiman; Mehdi Mirzaei; Stuart Graham; Vivek Gupta
Journal:  Cell Mol Life Sci       Date:  2022-03-04       Impact factor: 9.207

Review 7.  Neuroserpin: structure, function, physiology and pathology.

Authors:  Emanuela D'Acunto; Annamaria Fra; Cristina Visentin; Mauro Manno; Stefano Ricagno; Giovanna Galliciotti; Elena Miranda
Journal:  Cell Mol Life Sci       Date:  2021-08-17       Impact factor: 9.261

Review 8.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.